They even generated clinical results that suggested it might have promise as a weight-loss drug as well — only to have Pfizer, which had agreed to fund the research, withdraw its support ...

Pfizer's stock has underperformed, but management's focus on R&D and cost efficiencies should boost margins and free cash flow, supporting a Buy rating. Despite political headwinds, PFE's ...

Pfizer reiterated its forecast for 2024 and issued a new one for 2025. Management generally tried to calm some worries from rattled shareholders. There are still a couple of issues to be aware of ...

Global pharmaceutical manufacturer Pfizer is cutting 62 jobs at its Pfizer Connect facility in downtown Tampa. The company announced the cuts Dec. 20 in a letter to the state to meet federal Worker ...

Pfizer's management team recently announced sales and earnings expectations for 2025. An investment-bank analyst thinks Pfizer stock can shoot about 37% higher in 2025. Pfizer has raised its ...

Pfizer stock (NYSE: PFE) was up 5% on Tuesday, December 17, after the company announced an optimistic outlook for 2025. The company expects its revenue to be in the range of $61 billion to $64 ...

HCL Technologies, Bharat Electronics, LTI Mindtree, Siemens, and Sun TV Network are the top five companies with the largest estimated excess cash reserves, said the report. The IiAS assessment, drawn ...

Beata Zawrzel / NurPhoto via Getty Images Pfizer on Tuesday affirmed its full-year 2024 projections and issued 2025 revenue and adjusted profit guidance in line with analysts' estimates.

As one of the largest vaccine makers, Pfizer has a big part of its business hinging on potential immunization policy changes under the incoming Trump administration. So when vaccine skeptic Robert F.

After pulling off a surprise third-quarter beat and full-year guidance raise amid shareholder activism earlier this year, Pfizer now expects its 2025 revenues to come in the same range as in 2024.

Pfizer (NYSE:PFE) just dropped some solid news for investors: 2025 revenue projections are right where Wall Street expected, between $61 billion and $64 billion, with adjusted earnings per share ...